Adamis Pharmaceuticals Corporation

(ADMP) Trade

By |

Profile

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.

Contact Information

Website: www.adamispharmaceuticals.com
Email: info@adamispharma.com
Main Phone: +1 858 997-2400
Address: 11682 El Camino Real
Address 2: Suite 300
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92130

Issuer Information

Exchange: NSC
CEO: Dennis J. Carlo
Employees: 231
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News



Gathering Data... Please wait

Profile

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.

Contact Information

Website: www.adamispharmaceuticals.com
Email: info@adamispharma.com
Main Phone: +1 858 997-2400
Address: 11682 El Camino Real
Address 2: Suite 300
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92130

Issuer Information

Exchange: NSC
CEO: Dennis J. Carlo
Employees: 231
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 0.56 $ 0. (0.00%)
Last Price 0.56 Change $ 0. Change % 0.00 Tick N/A
Bid 0.57 Bid Size 600.00 Ask 0.59 Ask Size 100.00
Open N/A High N/A Low N/A Prev Close 0.56
Last Trade Volume 0 52 Wk Hi 3.29 52 Wk Low 0.48
Market Cap 34.5 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 61,438,109.00 EPS (TTM) -0.84 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Robert B. Rothermel 1,000
Richard C. Williams 1,000
Robert B. Rothermel 1,000
William C. Denby 1,000
Robert B. Rothermel 1,000
Last 10 Sell Shares
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
David J. Marguglio 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 10 10 10 10
Low Target Price Estimate 6.25 6.25 6.25 6.25
Mean Target Price Estimate 7.41 7.41 7.41 7.41
Standard Deviation 1.76 1.76 1.76 1.76
Date of Most Recent Estimate 05/17/18 05/17/18 05/14/18 05/17/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 2 2
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.25 1.25 1.33 1.33